Core Insights - Stereotaxis, Inc. (STXS) is a medical robotics company focused on developing devices for minimally invasive endovascular procedures, utilizing their proprietary Robotic Magnetic Navigation (RMN) platform, particularly in the field of electrophysiology [1] Company Overview - The company specializes in medical robotics, specifically targeting minimally invasive procedures [1] - Stereotaxis leverages its RMN platform to enhance the precision and effectiveness of electrophysiological interventions [1] Leadership and Expertise - The article mentions Myriam Hernandez Alvarez, who has extensive academic qualifications in electronics, telecommunication engineering, computer science, business management, and computer applications [1]

Financial Performance and Backlog - As of December 31, 2025, the company had approximately $9.1 million in system backlog, with an expectation that about 78% will be recognized as revenue in 2026[26] - The company reported a system backlog of approximately $14.4 million as of December 31, 2024, indicating growth in demand for its products[26] Acquisitions and Product Development - The company completed the acquisition of Access Point Technologies EP, Inc. on July 31, 2024, enhancing its in-house catheter development capabilities[28] - The acquisition of Access Point Technologies EP, Inc. on July 31, 2024, provides the company with the Map-iT portfolio, enhancing its offerings in traditional cardiac ablation procedures[43] - The MAGiC Sweep catheter received FDA 510(k) clearance in July 2025, marking a significant advancement in the company's product lineup[52] - The company has developed a proprietary MAGiC ablation catheter expected to receive regulatory clearance in Europe by 2025 and in the U.S. by early 2026, which will replace the currently used J&J catheters[67] Clinical Focus and Market Potential - The primary clinical focus is on electrophysiology, specifically cardiac ablation procedures, which represent a multi-billion-dollar market with significant growth potential[19] - The market for cardiac ablation procedures has grown rapidly, with an annualized procedure growth rate of approximately 10%[57] - The company estimates that approximately 4 million interventional cardiology procedures are performed annually in the U.S., with 10-15% classified as complex, requiring longer procedure times and potentially sub-optimal outcomes[63] Technology and Innovation - The GenesisX RMN System is designed to improve accessibility and reduce installation time compared to previous generations[22] - The Odyssey Solution and its next-generation counterparts, Synchrony and SynX, aim to enhance procedure efficiency and lab integration[23] - The robotic technology is expected to enable more complex procedures with improved patient outcomes and reduced x-ray exposure[33] - The robotic technology has been demonstrated in over 500 publications and more than 150,000 procedures, showing significant reductions in major complications and patient radiation exposure[36] - The Odyssey Solution integrates multiple diagnostic and imaging sources into a single user interface, improving clinical workflow and efficiency in interventional labs[39] Regulatory and Compliance - The company’s medical devices are subject to extensive regulation by the FDA, requiring 510(k) clearance or pre-market approval (PMA) for commercial marketing in the U.S.[99][101] - Most of the company's current products are classified as Class II devices requiring 510(k) clearances, while certain therapeutic devices are classified as Class III and require PMA[102] - The 510(k) clearance process typically takes between four to twelve months, but can take longer depending on the complexity of the device[104] - The company must comply with various international regulations, including obtaining CE Mark certification for marketing in the European Economic Area[110] - The company is subject to anti-kickback and false claims laws, which impose significant penalties for violations related to healthcare fraud and abuse[112] Competition and Market Position - The company faces competition from traditional catheter-based electrophysiology approaches and new products in the market, including next-generation mapping systems and non-RF ablation devices[94] - The company faces competition from four companies with FDA-cleared endovascular catheter navigation systems for electrophysiology procedures and two companies with CE Mark approved electromagnetic catheter navigation systems in Europe[95] - The company has developed its own line of robotically enabled medical devices, competing with other manufacturers of traditional interventional devices and magnetically enabled catheters[96] - The Odyssey/Synchrony Solution faces direct competition from established imaging companies and dedicated solution providers, with expectations of continued competitive pressure due to rapid technological advancements[97] - Key competitive factors in the market include capability, safety, efficacy, ease of use, price, quality, reliability, and effective sales support[98] Workforce and Employee Relations - As of December 31, 2025, the company had 131 employees, with 40 in research and development, 47 in sales and marketing, 26 in manufacturing and service, and 18 in general administrative activities[125] - The company emphasizes the importance of attracting and retaining top talent to succeed in the competitive medical device industry[122] - The company provides a comprehensive total rewards package, including annual bonuses, sales commissions, and a 5% discount on stock purchases for eligible employees[128] - The company emphasizes employee health and wellness, offering programs that support mental health, family care, and financial well-being[126] - The company engages in ongoing training and development, requiring compliance training and offering professional development courses[129] - The company maintains a positive relationship with employees, with a significant majority not covered by collective bargaining agreements[125] - The company operates in 11 different countries, reflecting a diverse global workforce[124] - The company is committed to fostering a culture of mutual respect and dignity among employees[124] - The company conducts annual global performance reviews to assess employee performance and compensation[129] - The company invests in employee safety and wellness programs, adhering to regional and local regulations[127] Transparency and Communication - The company makes SEC filings available on its website, ensuring transparency and accessibility of financial information[130]

Management View - Stereotaxis, Inc. CEO David Fischel described 2025 as a year of "tremendous progress," highlighting technological and commercial advancements despite ongoing challenges [2] - The company aims to pioneer robotics within minimally invasive endovascular surgery, emphasizing its commitment to innovation in this field [2]

Core Insights - The company achieved significant regulatory approvals in 2025 for its GenesisX robot and MAGiC catheter products, marking a pivotal moment for its commercial strategy in complex electrophysiology (EP) procedures [1][3][6] - The company is transitioning to a business model that emphasizes recurring revenue through a mix of sales, leases, and disposable commitments, which is expected to enhance revenue generation [6][7][8] Regulatory Approvals and Market Focus - In 2025, the company received U.S. and European regulatory approvals for the GenesisX robot and MAGiC catheter products, which are crucial for its focus on complex EP procedures, including congenital heart disease and ventricular tachycardia [1][6] - The EP market is substantial, treating approximately 2 million patients annually and generating over $13 billion in device revenue [1] Financial Performance - The company reported a revenue increase to $32.4 million in 2025, up from $26.9 million in 2024, with a fourth-quarter revenue of $8.6 million, reflecting a 36% year-over-year growth [4][18] - System revenue for 2025 was $10.2 million, while recurring revenue reached $22.2 million, driven by increased catheter sales [18] Manufacturing and Production Challenges - The company plans to produce approximately one GenesisX system every two months in 2026, with potential to scale production significantly [5][10] - Manufacturing of the MAGiC catheter has faced challenges, with production expected to ramp up to about 500 catheters per month by year-end 2026 [10][11] Strategic Priorities for 2026 - The company aims to establish at least five active GenesisX programs and transition existing EP customers to proprietary catheters as supply improves [12][13] - Plans include expanding the product platform beyond EP with new products and regulatory submissions, as well as enhancing its digital surgery suite [15][16] Future Outlook - The company anticipates double-digit revenue growth in 2026, with full-year revenue expected to exceed $40 million, driven by both system sales and recurring revenue [4][22] - Operating expenses are projected to remain stable as the company reallocates resources towards manufacturing and commercialization efforts [22]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 totaled $8.6 million, a 36% increase compared to $6.3 million in Q4 2024 [29] - Full year revenue for 2025 was $32.4 million, up from $26.9 million in 2024 [29] - Gross margin for Q4 2025 was approximately 50%, while the full year gross margin was about 53% [30] - Operating loss for Q4 2025 was $5.6 million, compared to $7.6 million in Q4 2024 [31] - Adjusted operating loss for the full year 2025 was $9.3 million, improved from $12.4 million in 2024 [32] Business Line Data and Key Metrics Changes - System revenue for Q4 2025 was $3.3 million, reflecting partial revenue recognition on two Genesis systems [29] - Recurring revenue for Q4 2025 was $5.3 million, down from $9.4 million in Q4 2024, impacted by initial sales of new catheters [29] - Full year system revenue was $10.2 million, compared to $8.6 million in the prior year [29] - Full year recurring revenue was $22.2 million, up from $18.3 million in 2024, driven by increased catheter revenue [30] Market Data and Key Metrics Changes - The electrophysiology (EP) market is projected to grow from over $13 billion annually to $20 billion by 2030 [11] - The company views the market opportunity for robotics in EP as a $2 billion opportunity [12] Company Strategy and Development Direction - The company aims to pioneer robotics in minimally invasive endovascular surgery, focusing on making its robot widely available without requiring significant construction [9] - The strategy includes building an ecosystem of catheters, leveraging core technology for broader endovascular surgery applications, and establishing a digital backbone for connectivity [10] - Regulatory approvals for the GenesisX robot and associated catheters were achieved, marking a significant milestone [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in overcoming manufacturing challenges and anticipates significant commercial and strategic value creation in 2026 [19] - The company expects to deliver double-digit revenue growth in 2026, with quarterly revenue projected to ramp above $10 million in the latter half of the year [34] - Management highlighted the importance of establishing GenesisX programs and ramping catheter manufacturing to support revenue growth [19][21] Other Important Information - The company generated $4 million from a registered direct financing and $3.1 million from an at-the-market offering [33] - Cash and cash equivalents as of December 31, 2025, were $13.4 million with no debt [33] Q&A Session Summary Question: What is the goal for GenesisX programs and the mix of sales? - Management expects Genesis sales to continue at a similar pace as previous years, with mid-single digit numbers of Genesis systems sold annually [38] Question: What is included in the $3 million revenue goal for Synchrony in 2026? - The revenue guidance focuses on capital sales of Synchrony systems, with expectations for several hospitals to standardize their EP labs on Synchrony [41] Question: How is the allocation of MAGiC catheters being managed amid manufacturing constraints? - Management acknowledged the challenge of ramping manufacturing and is working closely with physicians to manage expectations and supply [46] Question: What are the economic models for GenesisX placements? - There are three core models: outright capital sale, lease, and placement with disposable commitments, with a mix expected in deals [71] Question: What is the outlook for operating expenses in 2026? - Management expects operating expenses to remain stable year-over-year, with adjustments based on project milestones and investments in manufacturing and commercial activities [80]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 totaled $8.6 million, a 36% increase from $6.3 million in Q4 2024 [30] - Full year 2025 revenue was $32.4 million compared to $26.9 million in 2024 [30] - Gross margin for Q4 and full year 2025 was approximately 50% and 53% respectively [31] - Operating loss for Q4 2025 was $5.6 million, improved from $7.6 million in Q4 2024 [32] - Negative free cash flow for the full year was $13.8 million, compared to $8.5 million in 2024 [33] Business Line Data and Key Metrics Changes - System revenue for Q4 was $3.3 million, up from $1.4 million in the prior year [30] - Recurring revenue for Q4 was $5.3 million, down from $9.4 million in the prior year [30] - Full year system revenue was $10.2 million compared to $8.6 million in the prior year [30] - Full year recurring revenue was $22.2 million, up from $18.3 million in the prior year [31] Market Data and Key Metrics Changes - The electrophysiology (EP) market is projected to grow from over $13 billion to $20 billion by 2030 [14] - The company views the market opportunity for robotics in EP as $2 billion [15] Company Strategy and Development Direction - The company aims to pioneer robotics in minimally invasive endovascular surgery, focusing on making its robot widely available and building an ecosystem of catheters [10][11] - Key strategic pillars include rapid installation of robots, reducing dependencies on third-party catheters, leveraging core technology for broader applications, and establishing a digital backbone for connectivity [10][11] - The company achieved regulatory approvals for the GenesisX robot and associated catheters, marking a significant milestone [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving double-digit revenue growth in 2026, with expectations for quarterly revenue to ramp above $10 million in the latter half of the year [35] - The company anticipates a working capital benefit to cash flow in 2026 after significant investments in working capital in 2025 [36] - Management is optimistic about overcoming manufacturing challenges and expects to establish a strong foundation for future growth [29] Other Important Information - The company has a cash balance of $13.4 million and no debt as of December 31 [34] - Manufacturing challenges have been a focus, particularly with the MAGiC catheter, which faced production issues [22][74] Q&A Session Summary Question: What is the goal for GenesisX programs and sales expectations? - Management expects Genesis sales to continue at a similar pace as previous years, with mid-single digit numbers of Genesis systems sold annually [39] Question: What is the revenue goal for Synchrony in 2026? - The revenue goal includes capital sales and recurring revenue from service contracts and software subscriptions, with several hospitals expected to standardize their EP labs on Synchrony [43] Question: How is the allocation of MAGiC catheters being managed amid manufacturing constraints? - Management acknowledged the challenge of ramping manufacturing and is working to ensure that administrative efforts are in place to meet demand as production increases [49] Question: What are the economic models for GenesisX? - Three core models are being utilized: outright capital sale, leasing, and placement with disposable commitments, allowing flexibility in revenue generation [76] Question: What is the outlook for the Chinese market? - The company expects the first Genesis systems to be sold in China this year, with ongoing efforts to transition to new catheter systems and regulatory submissions [90]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 totaled $8.6 million, a 36% increase from $6.3 million in Q4 2024 [21] - Full year revenue for 2025 was $32.4 million, compared to $26.9 million in 2024 [21] - Gross margin for Q4 and full year 2025 was approximately 50% and 53% respectively [22] - Operating loss for Q4 2025 was $5.6 million, compared to $7.6 million in Q4 2024 [23] Business Line Data and Key Metrics Changes - System revenue for Q4 2025 was $3.3 million, up from $1.4 million in the prior year [21] - Recurring revenue for Q4 2025 was $5.3 million, down from $9.4 million in Q4 2024 [21] - Full year system revenue was $10.2 million, compared to $8.6 million in the prior year [21] - Full year recurring revenue was $22.2 million, up from $18.3 million in the prior year [22] Market Data and Key Metrics Changes - The electrophysiology (EP) market is projected to grow from over $13 billion to $20 billion by 2030 [7] - The company views the congenital heart disease, pediatrics, and ventricular tachycardia market as a $2 billion opportunity [8] Company Strategy and Development Direction - The company aims to pioneer robotics in minimally invasive endovascular surgery, focusing on making its robot widely available and building an ecosystem of catheters [6] - The strategy includes four pillars: rapid installation of robots, building a catheter ecosystem, leveraging core technology for broader applications, and establishing a digital backbone [6] - The company plans to demonstrate the real-world value of GenesisX by establishing at least five active programs [12] Management's Comments on Operating Environment and Future Outlook - Management expects to deliver double-digit revenue growth in 2026, with quarterly revenue expected to ramp above $10 million in the latter half of the year [26] - The company anticipates a working capital benefit to cash flow in 2026 after significant investment in working capital in 2025 [27] - Management is confident in overcoming manufacturing challenges and is excited about the progress being made [12] Other Important Information - The company achieved regulatory approvals for the GenesisX robot and associated catheters in the U.S. and Europe [7] - Manufacturing challenges have been a focus, with plans to scale production of catheters significantly throughout the year [12] Q&A Session Summary Question: What is the goal of five GenesisX programs? - The company expects Genesis sales orders to continue at a similar pace as previous years, with mid-single digit numbers of Genesis systems sold annually [31] Question: What is included in the $3+ million revenue goal for Synchrony in 2026? - The revenue guidance focuses on capital sales of Synchrony systems, with several hospitals expected to standardize their EP labs on Synchrony [34] Question: How are catheters allocated to specific accounts given manufacturing constraints? - The company is managing demand and working through administrative efforts to ensure that as manufacturing ramps, they can meet the demand for MAGiC catheters [40] Question: What is the path to launching MAGiC with pulsed field ablation? - The company has conducted compatibility testing and is compiling a dossier for review by the EU notified body [46] Question: What is the expected operating expense for 2026? - The company expects operating expenses to remain stable year-over-year, with adjusted operating expenses projected to stay under $30 million [75]

Revenue Growth - Revenue for Q4 2025 was $8.6 million, a 36% increase from $6.3 million in Q4 2024[5] - Full year 2025 revenue totaled $32.4 million, representing a 20% increase compared to $26.9 million in 2024[5] - System revenue for 2025 grew 18% to $10.2 million, while recurring revenue increased by 21% to $22.2 million[5] - Stereotaxis anticipates annual revenue to surpass $40 million in 2026, with double-digit growth expected[10] Profitability and Loss - Gross margin for Q4 2025 was approximately 50%, and for the full year, it was 53%[6] - Operating loss for Q4 2025 was ($5.6) million, an improvement from ($7.6) million in Q4 2024[8] - Adjusted operating loss for the full year 2025 was ($9.3) million, compared to ($12.4) million in the prior year[8] Cash and Assets - Cash and cash equivalents at December 31, 2025, were $13.4 million, with no debt[9] - Total current assets increased to $33,849,000 in 2025 from $26,439,000 in 2024, representing a growth of 28.8%[19] - Accounts receivable rose to $5,847,000 in 2025, up from $3,824,000 in 2024, marking a 52.9% increase[19] - Total assets reached $52,251,000 in 2025, compared to $46,724,000 in 2024, reflecting an increase of 11.4%[19] Liabilities and Equity - Total liabilities decreased to $33,530,000 in 2025 from $35,292,000 in 2024, a reduction of 5.0%[19] - Stockholders' equity significantly increased to $13,481,000 in 2025, up from $6,080,000 in 2024, representing a growth of 121.5%[19] - Additional paid-in capital rose to $596,960,000 in 2025 from $567,926,000 in 2024, an increase of 5.1%[19] - The accumulated deficit widened to $(583,368,000) in 2025 from $(561,725,000) in 2024[19] - Current liabilities totaled $22,360,000 in 2025, slightly up from $21,602,000 in 2024, an increase of 3.5%[19] - The company reported a decrease in long-term contingent consideration to $4,724,000 in 2025 from $6,126,000 in 2024, a decline of 22.9%[19] - The operating lease liabilities decreased to $4,794,000 in 2025 from $5,436,000 in 2024, a reduction of 11.8%[19] Manufacturing and Backlog - The company aims to ramp manufacturing of MAGiC to 500 catheters per month by year-end 2026[7] - System backlog at the start of 2026 is $9.1 million[5]

Core Insights - Stereotaxis reported a revenue growth of over 20% for the year 2025, driven by significant regulatory approvals and advancements in their product pipeline [2][4] - The company achieved regulatory approvals for key products including the GenesisX robot and MAGiC catheters, which are expected to drive future commercial growth [3][4] Financial Performance - Fourth quarter revenue for 2025 was $8.6 million, a 36% increase from $6.3 million in Q4 2024 [4] - Full year revenue for 2025 totaled $32.4 million, representing a 20% increase from $26.9 million in 2024 [4] - System revenue for the full year grew 18% to $10.2 million, while recurring revenue increased by 21% to $22.2 million [4] Gross Margins and Expenses - Gross margin for Q4 2025 was approximately 50%, while the full year gross margin was about 53% [5] - Operating expenses for Q4 2025 were $10.0 million, with adjusted operating expenses at $7.0 million after excluding non-cash charges [5] Losses - The operating loss for Q4 2025 was ($5.6) million, an improvement from ($7.6) million in Q4 2024 [6] - For the full year 2025, the adjusted operating loss was ($9.3) million, compared to ($12.4) million in 2024 [7] Cash Position - As of December 31, 2025, Stereotaxis had cash and cash equivalents of $13.4 million and no debt [8] - The company raised $3.1 million through an at-the-market offering during Q4 2025 [8] Future Outlook - Stereotaxis anticipates double-digit revenue growth for 2026, expecting annual revenue to surpass $40 million [9] - The company aims to achieve four key milestones in 2026 to support future growth [6][9]

Core Viewpoint - Stereotaxis will release its financial results for the fourth quarter and full year of 2025 on March 9, 2026, and will host a conference call to discuss these results and corporate developments [1]. Group 1: Financial Results Announcement - The financial results will be announced at the close of U.S. financial markets on March 9, 2026 [1]. - A conference call and webcast will take place at 4:30 p.m. ET on the same day [2]. Group 2: Conference Call Details - The dial-in number for the live call is 800-715-9871 for the U.S. and Canada, and 646-307-1963 for international participants, with a participant passcode of 8365695 [2]. - A replay of the call will be available for one month starting approximately four hours after the call ends [2]. Group 3: Company Overview - Stereotaxis is a leader in surgical robotics for minimally invasive endovascular intervention, focusing on the development of robotic systems and solutions for interventional laboratories [3]. - The technology has been utilized to treat over 150,000 patients globally, enhancing patient care and operational efficiency in the operating room [3].